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Global ubiquitination analysis 
reveals extensive modification 
and proteasomal degradation 
of cowpox virus proteins, but 
preservation of viral cores
Marica Grossegesse1, Joerg Doellinger1,2, Annemarie Fritsch1, Michael Laue3, Janett Piesker3, 
Lars Schaade4 & Andreas Nitsche1
The emergence of Variola virus-like viruses by natural evolution of zoonotic Orthopoxviruses, like 
Cowpox virus (CPXV), is a global health threat. The proteasome is essential for poxvirus replication, 
making the viral components interacting with the ubiquitin-proteasome system attractive antiviral 
targets. We show that proteasome inhibition impairs CPXV replication by prevention of uncoating, 
suggesting that uncoating is mediated by proteasomal degradation of viral core proteins. Although 
Orthopoxvirus particles contain considerable amounts of ubiquitin, distinct modification sites are 
largely unknown. Therefore, for the first time, we analyzed globally ubiquitination sites in CPXV 
mature virion proteins using LC-MS/MS. Identification of 137 conserved sites in 54 viral proteins 
among five CPXV strains revealed extensive ubiquitination of structural core proteins. Moreover, 
since virions contained primarily K48-linked polyubiquitin, we hypothesized that core proteins are 
modified accordingly. However, quantitative analysis of ubiquitinated CPXV proteins early in infection 
showed no proteasomal degradation of core proteins. Instead, our data indicate that the recently 
suggested proteasomal regulation of the uncoating factor E5 is a prerequisite for uncoating. Expanding 
our understanding of poxvirus uncoating and elucidating a multitude of novel ubiquitination sites in 
poxvirus proteins, the present study verifies the major biological significance of ubiquitin in poxvirus 
infection.
The ubiquitin-proteasome system (UPS) is exploited by members of most virus families1 and is essen-
tial for the replication of different virus families, e.g. Pox-2–4, Reo-5 and Coronaviridae6. As a member of the 
Poxviridae family the genus Orthopoxvirus (OPV) comprises complex enveloped DNA viruses, including the 
smallpox-causing Variola virus (VARV), Vaccinia virus (VACV), which was used for smallpox eradication7, and 
several animal-borne viruses with zoonotic potential like Cowpox virus (CPXV)8–10. Having caused the death of 
hundreds of millions of people, VARV is the most prominent member of OPV. Although VARV has been erad-
icated in 1979, it is still a global health threat because of its possible release in the context of a bioterrorist attack 
and the emergence of VARV-like viruses from circulating OPV by natural evolution11. CPXV are well suited to fill 
the niche that was created by VARV eradication, since it has the largest OPV genome including homologous open 
reading frames of all VARV genes. Currently, the number of zoonotic infections in Europe caused by CPXV is 
increasing, illustrating the need for a comprehensive understanding of the virus biology, especially the interaction 
with the host cell12,13.
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The ubiquitin-proteasome pathway is highly modulated during OPV infection, e.g. by virus-encoded ubiqui-
tin ligases or viral BTB/kelch and ANK/PRANC proteins that interact with cellular ubiquitin ligases14,15. OPV do 
not encode viral ubiquitin, but host ubiquitin locates to viral replication sites during infection16. Additionally, sev-
eral proteome studies identified ubiquitin as part of the VACV and CPXV mature virion17–19 and it was found to 
be more than 100-fold enriched in OPV particles compared to human cells17. Although ubiquitin is obviously an 
important poxvirus protein modification, only sparse information is available about ubiquitinated virus proteins.
Infectious OPV particles consist of a DNA-containing core which is surrounded by one or two membranes, 
resulting in intracellular mature virions (IMV) or extracellular enveloped virions (EEV), respectively. Two lateral 
bodies (LBs) are located between core and membrane, which are assumed to deliver viral enzymes into the host 
cell cytoplasm early in infection20. Poxvirus replication exclusively takes place within the cytoplasm of the host 
cell. Upon entry, the intact core is delivered into the cytoplasm, followed by early viral gene expression inside the 
core. After the viral DNA is released by core uncoating, replication as well as intermediate, and late viral gene 
expression proceed in delimited cytoplasmic areas called virus factories (VF)21,22.
The role of the UPS in OPV infection has been mostly analyzed using VACV, which is the best characterized 
OPV. Treatment of HeLa cells with proteasome inhibitors led to reduced viral titers and impaired intermediate 
and late viral gene expression, while early viral gene expression still occurred. Also, the prevention of VACV-DNA 
replication and VF formation was observed in the context of proteasome inhibition2–4. This is consistent with the 
finding that proteasome activity is required for VACV genome uncoating4.
In contrast to VACV, the role of the UPS during CPXV infection has been barely investigated so far. Treatment 
of CPXV-infected cells with proteasome inhibitors prevents late protein expression and reduces viral titers3 but 
it remains unknown to what extent results generated with VACV apply to CPXV. Hence, we aimed to charac-
terize the role of ubiquitin and the UPS in CPXV infection in a more comprehensive way. We initially verified 
the inhibition of proteasome activity by MG-132 and Bortezomib in HeLa cells and excluded cytotoxic effects. 
Subsequently, we showed that proteasome inhibition impairs CPXV replication by prevention of viral core deg-
radation, resulting in early but not in late viral protein expression. Therefore, we hypothesized that proteasomal 
degradation of K48-linked polyubiquitinated core proteins is the mechanism underlying CPXV uncoating, as 
previously suggested for VACV4. Since this hypothesis has not been verified yet, we aimed to prove it by con-
ducting the first global LC-MS/MS-based ubiquitinome analysis of OPV IMV proteins. Using purified CPXV 
IMV particles, we identified 137 conserved ubiquitination sites in 54 viral proteins among five CPXV strains. 
As hypothesized, CPXV major core proteins were extensively ubiquitinated. But surprisingly, we were unable to 
detect their proteasome-dependent degradation upon infection. Instead, 54 other viral proteins were degraded in 
a proteasome-dependent manner early in infection, including all proteins associated with the formation of viral 
pre-replication sites23. Most notably, we detected the proteasomal degradation of the uncoating factor E5 (VACV 
D5), which is likely a prerequisite for OPV genome uncoating23.
Our data deepen the understanding of OPV genome uncoating and provide evidence of extensive ubiquitin 
modification in OPV proteins. Moreover, the multitude of novel modification sites identified in OPV proteins of 
diverse functions underlines that the biological significance of ubiquitination for OPV is far from being restricted 
to uncoating.
Results and Discussion
MG-132 and Bortezomib inhibit proteasome activity without inducing cytotoxic effects. In 
order to analyze the effect of proteasome inhibition on CPXV replication, the proteasome activity in HeLa 
cells treated with two different inhibitors was tested. For this purpose, different concentrations of MG-132 and 
Bortezomib were analyzed for their inhibition of the chymotryptic-like proteasome activity in HeLa cells. Both 
compounds inhibit primarily the chymotrypsin-like site of the 26 S proteasome but may also act on the caspase-
like site in a concentration-dependent manner24. A complete inhibition of proteasome activity was only observed 
using 10 µM MG-132 and 1 µM Bortezomib, which represented the highest inhibitor concentrations tested 
(Fig. 1a). These concentrations have already been applied in previous studies, though proteasome inhibition has 
not been shown2,3. Analysis of the ATP amount revealed about 80% cell viability of inhibitor-treated cells after 
Figure 1. Effect of proteasome inhibitors on HeLa cells. HeLa cells were incubated for 24 h in the presence of 
MG-132, Bortezomib or DMSO and assayed for (a) chymotrypsin-like proteasome activity, (b) ATP amount 
and (c) release of lactate dehydrogenase. Error bars indicate means ± standard deviation of one experiment 
performed at least in triplicate. Statistics: One-way ANOVA and Bonferroni’s multiple comparisons test 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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24 h of treatment (Fig. 1b). Inhibitor-induced release of lactate dehydrogenase, as a measure of cytotoxicity, was 
below 5% (Fig. 1c), confirming acceptable conditions for infection experiments.
Proteasome inhibition impairs CPXV replication, virus factory formation and late protein synthesis. 
Since reduction of CPXV infectious particles has only been described for proteasome inhibition using 
Bortezomib3, we tested the effect of MG-132 which is the inhibitor primarily used for studies with VACV2–4. 
We were able to confirm a reduction of CPXV genome copies and plaque-forming units (PFU) in HeLa cells 
treated with either Bortezomib or MG-132 (Fig. 2). Inhibition of late protein expression has only been shown 
using MG-1323, while inhibition of VF formation has not been shown for CPXV at all. HeLa cells infected with 
a recombinant CPXV strain expressing differently fluorescent proteins under control of an early and a late viral 
promotor revealed the absence of late protein expression in inhibitor-treated cells while early protein expression 
was still detectable (Fig. 3a). Additionally, VF were only detected in control cells with non-inhibited proteasome, 
while VF were absent in cells with inhibited proteasome (Fig. 3b). Taken together, we demonstrated that the 
effects of proteasome inhibition observed for VACV replication are transferable to CPXV.
Proteasome inhibition leads to intact virus cores in the cytoplasm. The absence of late protein 
expression and viral genome replication has been hypothesized to result from the inability of core uncoating. 
Therefore, we wondered whether we could detect intact CPXV cores in the cytoplasm of cells with inhibited 
proteasome as demonstrated for VACV2,4. Using electron microscopy, we were indeed able to detect intact 
CPXV cores in 72% of MG-132-treated cells, while only 1% of cells with non-inhibited proteasome showed 
intact core structures. Furthermore, VF were found in 77% of cells with non-inhibited proteasome, while no VF 
were detected in MG-132-treated cells (Fig. 3c). Both results suggest that CPXV virus replication is impaired by 
MG-132 treatment due to prevention of core uncoating.
Most previous data2,4,25, including our own, indicated that proteasome-dependent degradation of major core 
proteins is the mechanism underlying OPV genome uncoating. Using a confocal microscopy-based core stabili-
zation assay, Satheshkumar and colleagues still observed 40–45% of uncoated cores in cells treated with MG-132. 
Although they additionally observed a more than 2-fold increase in intact virus cores in the presence of MG-132, 
they concluded that the inability of uncoating is not sufficient to account for the complete replication inhibition of 
VACV observed in proteasome-inhibited cells2. However, virus attachment to cells at 4 °C for 1 h without the pres-
ence of MG-132 prior to 37 °C incubation in the presence of proteasome inhibitor, as done by Satheshkumar and 
colleagues2, may result in uncoating even before complete proteasome inhibition is achieved. This may explain 
the observed 40–45% of uncoated cores in the presence of MG-1322. We still observed residual proteasome activ-
ity after 1 h of MG-132 treatment (data not shown) verifying this assumption and hence we pretreated cells for 
electron microscopy with proteasome inhibitor prior to infection. Confirming that proteasome inhibition pre-
vents CPXV core degradation, we aimed to identify ubiquitination sites in structural core proteins, which are 
a prerequisite for their proteasome-dependent degradation. Therefore, we conducted the first global LC-MS/
MS-based ubiquitinome analysis of virion proteins.
Analysis of the CPXV mature virion ubiquitinome. Although K48-linked polyubiquitin was identified 
in VACV core fractions using immunoblotting4, no information is available about distinct ubiquitinated proteins 
in the core fraction that would prove the hypothesis of ubiquitinated structural core proteins. This encouraged 
us to analyze the mature virion ubiquitinome of five CPXV strains to elucidate the conserved CPXV ubiquitin-
ome. Besides the cell culture-adapted CPXV strain Brighton Red (BR) representing the best-characterized CPXV 
strain, we analyzed four CPXV strains that were isolated between 2007 and 2009 in the German Consultant 
Laboratory for Poxviruses at the Robert Koch Institute, Germany. All of these four strains led to documented 
zoonotic infections. If the hypothesis of ubiquitinated core proteins is true, ubiquitination sites in corresponding 
Figure 2. Proteasome inhibition leads to reduced CPXV genome equivalents and infectious particles. HeLa 
cells were infected with CPXV BR at an MOI of 1 in the presence or absence of 10 µM MG-132 or 1 µM 
Bortezomib. At 4 and 24 h post infection the amount of (a) viral genome equivalents (GE) and (b) plaque-
forming units (PFU) in the supernatant was analyzed. Error bars indicate means ± standard deviation of one 
experiment performed in triplicate. Statistics: One-way ANOVA and Bonferroni’s multiple comparisons test 
(*p ≤ 0.05, ****p ≤ 0.0001).
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proteins should be identifiable. Therefore, we purified CPXV mature virions by density gradient ultracentrifuga-
tion, lysed the purified particles and digested the proteins with trypsin. Ubiquitinated lysine residues resulted in 
diGly(K) remnants at peptides, which were subsequently enriched via immunoaffinity purification and analyzed 
by LC-MS/MS.
In total, between 656 and 1,230 diGly(K) peptides were identified from about 12,000 to 14,500 fragment spec-
tra, depending on the CPXV strain (Supplementary Table S1). About 50% of these peptides (based on peptide 
area quantification) contained at least one ubiquitination site, indicating a successful enrichment of diGly(K) pep-
tides. As expected, the proportion of missed cleavages was greatly increased for peptides with diGly(K) residue 
since trypsin cleavage is prevented by diGly(K) remnants26. Furthermore, it was not surprising that about 58% 
of ubiquitinated peptides (based on peptide area quantification) originated from ubiquitin itself. Viral peptides 
made up 34% of ubiquitinated peptides while only 8% originated from the host or contaminants (Supplementary 
Table S2). Hence, ubiquitin is probably derived from viral rather than host proteins. The ubiquitin-like proteins 
ISG15 and NEDD8 also result in diGly(K) remnants after trypsin digestion26, but since these peptides together 
made up less than 0.2% of all peptide areas, diGly(K) residues were considered to be ubiquitin specific.
Ubiquitin itself contains seven lysine residues at positions 6, 11, 27, 29, 33, 48 and 63 by which polyubiquitin 
chains can be built, leading to different downstream reactions27. While K48-linked polyubiquitin chains are estab-
lished to mediate proteasomal degradation, K63 linkages are associated with non-proteolytic functions27,28. Also, 
K11-linked polyubiquitin can lead to proteasomal degradation, while less is known about the fate of proteins 
tagged with K6, K27, K29 and K33 polyubiquitin chains27. All of the seven ubiquitin linkages possible were iden-
tified in all five CPXV strains, except for K33 which was not identified in the CPXV RatHei sample. Quantitative 
Figure 3. Proteasome inhibition impairs CPXV late protein expression and virus factory formation by 
prevention of uncoating. (a,b) HeLa cells were infected with CPXV BRFseR expressing RFP under an early viral 
promotor and GFP under a late viral promotor at an MOI of 5 in the presence or absence of 10 µM MG-132 or 
1 µM Bortezomib. After 8 h cells were fixed and stained with DAPI. (a) Inhibitor-treated cells display no late 
protein expression, while early protein expression is still detectable. RFP fluorescence in control cells is overlaid 
by GFP fluorescence and hence appears less intense. (b) While cells with non-inhibited proteasome (DMSO) 
display typical virus factories in the cytoplasm (white triangle), these structures were absent in proteasome 
inhibitor-treated cells. (c) HeLa cells were infected with CPXV BRFseR at an MOI of 100 in the presence of 
10 µM MG-132 or DMSO and subjected to transmission electron microscopy 4 h post infection. Virus factories 
and immature virus particles (white arrows) were only detected in cells treated with DMSO, while intact cores 
(black arrows) were regularly found in cells treated with proteasome inhibitor MG-132.
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approximation of lysine linkages using peptide areas of linkage-specific ubiquitin peptides revealed K48-linked 
polyubiquitin as the most abundant ubiquitin linkage in CPXV IMV particles, with a mean of 53% of all ubiqui-
tin linkages. K63 was identified to be the second-most abundant linkage, with a mean portion of 33% in CPXV 
mature virions. K11 and K6 represented about 8% and 4.5%, respectively, while K27 and K29 linkages made up 
less than 1% each (Fig. 4a and Supplementary Table S3). These abundances resemble the ubiquitin linkage fre-
quencies observed in cells29. Not surprisingly, it seems that the CPXV ubiquitin linkage abundance is well adapted 
to its host.
K48 is probably the predominant ubiquitin linkage in CPXV IMV proteins, indicating that at least some virion 
proteins are tagged for proteasomal degradation. This supports the hypothesis of K48-linked polyubiquitinated 
core proteins. It should be noted that peptide area quantification of ubiquitin linkages relies on the comparison 
of non-identical peptides and hence represents only a rough approximation. Moreover, from our results, it is not 
possibly to determine the precise ubiquitination linkage of distinct virion proteins. However, in agreement with 
our results, Mercer and colleagues identified K48-linked polyubiquitin in VACV virion core fractions by Western 
blotting but, in contrast to our results, they were not able to detect K63-linked polyubiquitin chains4. This might 
be attributed to the lesser abundance of K63 linkages which may not be detectable using Western blot but it may 
also represent a biological difference between VACV and CPXV. It should be noted further that fractionation of 
purified IMV particles in core and membrane fraction by incubation with detergent and reduction agents4,20,30 
as performed by Mercer and colleagues4 may result in incomplete separation since LBs may be still associated. 
Pederson and colleagues compared proteins of cores prepared with NP-40/DTT to those isolated from infected 
cells treated with actinomycin D which inhibits uncoating. Only the NP40/DTT-treated cores were positive for 
the LB protein F17, which indicates incomplete LB removal by NP40/DTT treatment25. Although LBs may be 
partially removed by trypsin digestion20, no conclusion can be drawn which distinct viral proteins are ubiquiti-
nated when analyzing core and membrane fraction by immunoblot. The LC-MS/MS-based ubiquitinome analysis 
performed in this study enabled us to map ubiquitination sites in viral proteins precisely, with diGly(K) residues 
providing direct evidence of ubiquitination.
The detection of diverse ubiquitin linkages in CPXV particles does not necessarily imply that these chains are 
covalently bound to a target protein, as free ubiquitin chains have been identified in cells31,32. Preformed ubiquitin 
chains can also be transferred to substrates by ubiquitin ligases33. However, Mercer and colleagues concluded 
from the molecular weight of K48-linked ubiquitin bands in immunoblot analysis that ubiquitin in VACV parti-
cles was substrate bound4.
Furthermore, the number of viral ubiquitination sites somewhat correlated with the ubiquitin amount in the 
virus particles (proteome analysis prior to diGly(K) enrichment; data not shown) and ranged from 247 in CPXV 
Figure 4. Conserved ubiquitination sites and lysine linkages in CPXV mature virions. (a) Quantitative 
approximation of lysine linkages in CPXV IMV particles using linkage-specific peptide areas. Shown is 
the mean ± standard deviation of five CPXV strains in % of total ubiquitin diGly(K) peptide area. (b) Number 
of conserved ubiquitination sites in CPXV proteins. (c) CPXV proteins with conserved ubiquitination sites 
grouped by function. Shown is the number of proteins (in parenthesis) associated with a distinct function.
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BR to 668 in CPXV HumGri which were assigned to 86 to 148 viral proteins (Table 1). This data indicates possible 
strain-specific differences in the CPXV ubiquitinome.
The conserved CPXV mature virion ubiquitinome. We were interested in identifying conserved ubiq-
uitination sites among the five analyzed CPXV strains, since these sites might be functionally more important than 
non-conserved sites. A list of all identified ubiquitination sites in each CPXV strain is provided in Supplementary 
Table S4. In total, 137 conserved ubiquitination sites were identified, considering also homologous lysine residues 
of proteins with sequence difference between strains. These sites were assigned to 54 CPXV proteins, all belonging 
to the conserved CPXV mature virion proteome except for A36 (Table 2 and Supplementary Table S5)17.
Assuming 152 viral proteins in CPXV mature virion particles17, we demonstrate that at least 35% of CPXV 
mature virion proteins are ubiquitinated at conserved lysine residues, underlining the overall importance of ubiq-
uitination for OPV. Another eleven viral proteins contained ubiquitination sites in all five CPXV strains but no 
conserved lysine residues were identified (Supplementary Table S6). More than half of the 54 viral proteins with 
conserved ubiquitination sites contained one or two diGly(K) sites, while other proteins showed up to ten sites 
(Fig. 4b). As expected, proteins with conserved diGly(K) sites tended to be essential for virus replication (59.5%) 
and conserved in OPV (70.4%). In addition, most viral proteins with conserved ubiquitination sites belonged to 
the functional term host–virus interaction and transcription but also proteins belonging to the core were identi-
fied (Fig. 4c). The identification of ubiquitination sites in CPXV proteins of diverse functions indicated an under-
estimated regulatory function of ubiquitin during OPV infection. Because the elucidation of ubiquitination sites 
in CPXV core proteins was a major objective of the present study, it is discussed in the following. Nevertheless, 
remarkable results were obtained for viral proteins of other functional classes. Our data, for example, indicates a 
ubiquitin-dependent transcriptional regulation of CPXV. Therefore, viral proteins with conserved ubiquitination 
sites that belong to functional classes other than the core are depicted in the Supplementary Discussion.
Ubiquitination of CPXV core proteins. Although proteins of the core are not defined in detail, they are 
known to include the viral proteins A11 (p4a), A4 (p4b), A5 (p39), N4 (p25) and A7 transferred by homology 
from VACV25,34,35. These proteins, except for A7, are also found in high copy numbers comparable to those of 
membrane proteins in CPXV mature virions, suggesting a structural role17. The function of A7 has not been elu-
cidated yet. A7 and N4 are known to locate inside the core, while A11, A4 and A5 are part of the outer core struc-
ture, making them likely targets for ubiquitination25,35. The major core protein A11 contained the greatest number 
of ubiquitination sites among all proteins identified. A11 contained ten conserved diGly(K) sites and a mean of 
20 diGly(K) sites, considering also non-conserved sites. Additionally, the major core protein A4 contained six 
conserved diGly(K) sites, ranking third-highest in the number of conserved ubiquitination sites. The A5 protein 
was not grouped to the proteins with conserved ubiquitin positions because no site was detected in the CPXV BR 
strain; all other CPXV strains showed at least one ubiquitination site in the A5 protein. Although N4 and A7 are 
not part of the outer core structure, they were identified to possess six and seven conserved ubiquitination sites, 
respectively, demonstrating that ubiquitination of core proteins is not restricted to the outer part of the core. This 
data clearly confirmed the massive ubiquitination of CPXV major core proteins, supporting the hypothesis of 
their proteasomal degradation upon infection.
Ubiquitination of CPXV mature virion proteins may be catalyzed by one or numerous cellular E3 ubiquitin 
ligases36 or by a viral-encoded ubiquitin ligase14. CPXV encode one E3 ubiquitin ligase, the C7 protein (p28), 
which catalyzes K63-linked polyubiquitination in vitro15. Also the accumulation of K48-linked polyubiquitin 
in VF has been shown to be promoted by p2837. Additionally, it is assumed that at least one cellular ubiquitin 
ligase recruits ubiquitin to VF37. P28 is expressed early in infection and locates with ubiquitin to VF16,37, making 
the K48-linked polyubiquitination of CPXV mature virion proteins catalyzed by p28 an attractive hypothesis. 
However, p28 has been shown to be essential only for replication of ectromelia virus38 in mouse macrophages, 
suggesting the compensative activity of another ubiquitin ligase in cells other than macrophages.
Summarized, our results confirm previously described ubiquitination sites, as depicted in more detail in the 
Supplementary Discussion. Furthermore, distinct ubiquitination sites were elucidated in viral proteins which 
have been associated with ubiquitin before, but whose modification sites were previously unknown. However, 
there are some discrepancies between known ubiquitination sites in VACV and those identified in CPXV that 
may reflect species-specific differences. For example, it has been reported that VACV C6 (CPXV C14) and B14 
(CPXV B12) are not covalently ubiquitinated39. Indeed, for the CPXV BR strain we were unable to identify any 
ubiquitination site in C14 or B12, but all other analyzed CPXV strains contained ubiquitination sites on one or 
CPXV strain Ubiquitin [µmol/g protein]a Number of viral diGly(K) sites Number of viral diGly(K) proteins
BR 0.52 247 86
RatKre 0.57 403 117
RatHei 0.52 476 127
HumBer 0.61 487 131
HumGri 1.23 668 148
Table 1. Ubiquitin amount, viral ubiquitination sites and associated viral proteins. aUbiquitin amount 
in non-diGly(K)-enriched virions calculated by total protein approach (TPA)61. By TPA method, protein 
concentrations can be estimated without spike-in standard, assuming that the spectral intensity is proportional 
to the protein abundance.
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Gene CPXVa Gene VACVb Number of diGly(K) sitesc Protein description
A11L 129 10 Major core protein 4a precursor
A7L 125 7 Protein A6
A44R 167 6 Profilin
A4L 122 6 Major core protein 4b
E13L 118 6 Scaffold protein D13
H1L 078 6 Metalloendopeptidase G1
J1L 099 6 Tyr/ser protein phosphatase
L1L 070 6 Telomere-binding protein I1
N4R 091 6 Core protein VP8
A26L 148 5 A-type inclusion protein A25
H8L 085 5 Assembly protein G7
J3L 101 5 IMV heparin-binding surface protein
A24R 143 4 Intermediate transcription factor 3 large subunit
D12L 002 3 TNF alpha receptor-like protein
G13L 052 3 Envelope protein F13
G17R 056 3 LB phosphoprotein F17
H4L 081 3 Glutaredoxin-2
A14L 132 2 Virion membrane protein A13
C3L 199 2 Putative uncharacterized protein
C8L 013 2 Interleukin 18-binding protein
E5R 110 2 Primase D5/uncoating factor
F6R 062 2 Putative uncharacterized protein
F8R 064 2 Membrane protein, ass. with IV/IMV and core
H2L 079 2 Entry/fusion complex component protein
M1L 032 2 Interferon antagonist K1L
Q1L 028 2 Inhibitor of TNF-R and TLR signaling
S1R 093 2 Virion protein J1
A17L 136 1 Virion membrane protein A16
A19R 138 1 Transcript termination protein A18
A1L 119 1 Viral late gene transcription factor 2
A23R 142 1 DNA Holliday junction resolvase A22
A25R 144 1 DNA-directed RNA polymerase 133 kDa polypeptide
A28L 150 1 14 kDa cell fusion protein
A30L 152 1 DNA-directed RNA polymerase 35 kDa subunit
A35R 157 1 EEV glycoprotein
A36R 158 1 Inhibitor of MHC class II antigen presentation
A50L 173 1 Putative uncharacterized protein
A52R 175 1 Putative uncharacterized protein
A53R 176 1 DNA ligase
A6R 124 1 DNA-directed RNA polymerase 19 kDa subunit
A8L 126 1 Early transcription factor 82 kDa subunit
B2R 184 1 Putative uncharacterized protein
B4R 187 1 EEV type-I membrane glycoprotein
C17L 025 1 Complement control protein C3
F3L 059 1 Double-stranded RNA-binding protein
F4L 060 1 DNA-directed RNA polymerase 30 kDa polypeptide
H10R 087 1 Myristoylated protein G9
H3R 080 1 Late transcription elongation factor G2
H5R 082 1 Putative nuclease G5
L7L 076 1 Viral core cysteine proteinase
N1R 088 1 Myristoylated IMV virion protein
N3L 090 1 IMV protein
O1R 095 1 Cap-specific mRNA (nucleoside-2′-O-)-methyltransferase
O4R 098 1 DNA-directed RNA polymerase 147 kDa polypeptide
Table 2. CPXV mature virion proteins with conserved ubiquitination sites. aaccording to CPXV GRI-90. 
baccording to VACV WR. cconserved in five analyzed CPXV strains.
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both proteins. Hence, ubiquitination may contribute to species- and strain-specific differences of OPV. As ubiq-
uitination may also depend on the host, it possibly also contributes to OPV adaptation to new hosts.
CPXV proteins do not contain a ubiquitination motif near target lysine residues. Having iden-
tified up to 668 ubiquitination sites in a single CPXV strain encouraged us to search for a primary structure 
motif. We compared the amino acid sequence around ubiquitinated lysine residues (+/− eight amino acids) 
to the non-ubiquitinated lysine background using motif-x40. However, this did not lead to any results. Also, 
the sequence logo analysis implemented in Perseus revealed no primary amino acid motif for ubiquitination. 
Therefore, it may be concluded that ubiquitination site specificity of CPXV mature virion proteins is independent 
of a distinct amino acid motif near target lysine residues. It is not completely understood what determines ubiq-
uitination site specificity but recently it was suggested that proteins destined for the proteasome contain three fac-
tors which are referred to as tripartite degron architecture41. These consist of a primary peptide motif recognized 
by an E3-ubiquitin ligase (degron), target lysine site(s) for ubiquitination and a disordered degradation initiation 
site. The degron can be distant from the target ubiquitination site, which could explain why no ubiquitination 
motif was identified near the lysine residue.
Besides ubiquitination, phosphorylation of VACV mature virion proteins has been globally analyzed with 
LC-MS/MS42,43. Recently, 396 unique phosphorylation sites among 83 VACV proteins have been identified43. 
Strikingly, about 70% of CPXV proteins with conserved ubiquitination sites were identified to contain phos-
phorylation sites in homologous VACV proteins. This correlation may be important since cross-talk between 
phosphorylation and ubiquitination has been described, e.g. the regulation of proteasomal degradation by phos-
phorylation44. Interestingly, the data from Ngo and colleagues43 revealed the greatest number of phosphorylation 
sites in VACV core proteins p4A and p4B with 17 and 34 unique phosphorylation sites, respectively, indicating 
that core proteins are packaged in a phosphorylated state in mature virions. Since it is known that phospho-
rylation motifs, so-called phosphodegrons, can serve as recognition signals for E3 ligases44, it can be hypothe-
sized that OPV proteins may contain phosphorylation motifs representing binding signals for ubiquitin ligases. 
Although Ngo and colleagues43 did not detect a phosphorylation motif in VACV proteins, they observed protein 
areas with frequent phosphorylation identifications, so-called phosphorylation clusters, which were also found 
in major core proteins p4A and p4B.
UPS-dependent degradation of viral proteins early in infection. As multiple ubiquitination sites in 
CPXV core proteins were elucidated, we next aimed to show their proteasome-dependent degradation in HeLa 
cells. For this purpose, we performed an LC-MS/MS-based quantitative analysis of ubiquitinated peptides in 
CPXV-infected HeLa cells in the presence or absence of MG-132 early in infection (2 h post infection). Control 
and inhibitor-treated samples were prepared in triplicate each, which show clear separation in hierarchical clus-
tering and principal component analysis (Fig. 5a,b). Statistical analysis revealed significant abundance differ-
ences of ubiquitinated peptides in cells with non-inhibited versus inhibited proteasome, with most viral peptides 
being stabilized in the presence of proteasome inhibitor (Fig. 5c and Supplementary Table S7). Stabilization of 
proteins as a result of proteasome inhibition implies that these proteins are degraded by an active proteasome. 
Controversially, one peptide of the viral RhoA-signaling inhibitor G11 protein was identified to be degraded by 
the proteasome, while two peptides of G11 were identified as not being degraded. Since it cannot be inferred from 
the present data which ubiquitination linkage is present at the respective lysine linkage, the ubiquitin linkages in 
G11 may be not linked by K48 and, hence, may be not associated with proteasomal degradation. However, pep-
tides of all other viral proteins showed clear tendencies for either degradation or not. Functional categorization of 
CPXV proteins degraded by the proteasome revealed mostly proteins of unknown function, followed by proteins 
belonging to host–virus interaction, transcription and DNA replication. Although proteins associated with host–
virus interaction and transcription were also abundant among CPXV proteins with conserved ubiquitination 
sites, only few correlations between viral proteins degraded by the proteasome and conserved ubiquitination sites 
were observed (Supplementary Table S7). Out of 54 viral proteins degraded by the proteasome, 45 are part of the 
CPXV mature virion proteome17 but only 11 were identified with conserved ubiquitination site.
According to our hypothesis, we expected ubiquitinated peptides of CPXV major structural core proteins to accu-
mulate upon proteasome inhibition. Surprisingly, we observed the opposite. Major core proteins A11 and A4 were 
unchanged or even less ubiquitinated when the proteasome was inhibited, disproving their direct proteasomal deg-
radation. The outer core protein A5 was not identified in this experiment, which is consistent with the fact that no 
ubiquitination sites in A5 were identified in the ubiquitinome analysis in the CPXV BR strain used in this experiment. 
Besides structural core proteins, proteins that showed a downregulation upon MG-132 addition were primarily host 
proteins. Generally, the downregulation of ubiquitination upon proteasome inhibition may be catalyzed by deubiquit-
inating enzymes. It is not known how ubiquitination of proteins is altered during CPXV infection. However, since no 
deubiquitinating enzyme in CPXV has been described, host deubiquitinating enzymes may be involved.
Subsequently, we focused on the identification of CPXV proteins other than core proteins that could explain 
the inhibition of viral replication as a result of proteasome inhibition, and another class of viral proteins attracted 
our attention. Using siRNA screening, Kilcher and colleagues identified 15 viral candidate genes that impaired 
intermediate but not early VACV gene expression23. Out of these 15 candidate genes, four reduced the number 
of pre-replication sites, meaning precursor sites of viral DNA replication, by more than 40%. Strikingly, all of 
these four proteins were found to be stabilized by proteasome inhibition in our study. These proteins include 
the serine/threonine-protein kinase B1 (CPXV B1), the putative nuclease G5 (CPXV H5), the ssDNA-binding 
phosphoprotein I3 (CPXV L3) as well as the primase D5 (CPXV E5). Kilcher and colleagues identified the VACV 
D5 protein as the genome uncoating factor the depletion of which leads to accumulation of intact cores in the 
cytoplasm23. D5 has been shown to possess N-terminal primase as well as C-terminal NTPase activity in vitro45–48. 
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While both activities are essential for viral DNA replication, only the latter is essential for uncoating23. D5 is 
expressed early during infection and recruited to VACV cores in cells with inhibited proteasome but not in cells 
with non-inhibited proteasome, indicating a temporary localization which is reversed by the proteasome23. CPXV 
E5 and VACV D5 share about 98.5% amino acid identity. In this study we provide evidence that the CPXV D5 
homologue is ubiquitinated at two conserved lysine residues and degraded by the proteasome early in infection, 
supporting the hypothesis of a proteasomally regulated D5-core interaction. It has been proposed that D5 may 
assist uncoating by actively contributing to global core degradation or by acting at defined core channels23. Our 
data do not exclude the proteasome-dependent degradation of CPXV core proteins at a later stage of infection but 
indicate that the proteasomal degradation of other viral proteins, probably the uncoating factor D5 homologue, 
is a prerequisite. Other viral proteins that were identified to be proteasomally degraded early in infection are 
discussed in the supplements.
Besides 54 viral proteins, we found 151 ubiquitinated host proteins that significantly differed in abundance in 
response to proteasome inhibition of CPXV-infected cells (Supplementary Table S8). It should be noted that the 
identification of host proteins was not a major aim of this study. Hence, peptides were not fractionated prior to 
LC-MS/MS analysis as recommended for the detection of thousands of ubiquitination sites in cell lines26.
Conclusions
The UPS plays an important role not only during OPV infection2,3,23 but also during infection of viruses belonging 
to diverse other families5,6, demonstrating the general regulatory function of ubiquitin in viral infection.
In this study, we present the first global ubiquitination site analysis of CPXV mature virion proteins, which is, 
moreover, the first published ubiquitinome analysis of any virus particles. The identified modification sites pro-
vide the basis for the elucidation of associated biological processes which we showed using the example of uncoat-
ing. In doing so, we disproved the hypothesized degradation of polyubiquitinated OPV core proteins immediately 
upon infection. Instead, we hypothesize from our data that the proteasomal reversion of the interaction between 
E5 and viral core proteins is a prerequisite for OPV genome uncoating.
Since the established protocol is applicable to analyze differences in the ubiquitination status of virus proteins 
during infection in a global approach, the present study provides the groundwork for future proteomic studies to 
elucidate the diverse roles of ubiquitin during viral infections.
Figure 5. Proteasome-mediated degradation of ubiquitinated peptides at an early stage of CPXV infection. 
HeLa cells were infected in triplicate with CPXV BR at an MOI of 50 in the presence or absence of 10 µM MG-
132. After 2 h post infection ubiquitinated peptides were analyzed by MS. Plots show normalized ubiquitinated 
peptide areas. (a) Cluster analysis reveals ubiquitinated peptides that are more abundant when the proteasome 
is inhibited (samples MG_1 to 3) compared to cells with non-inhibited proteasome (samples C_1 to 3), 
indicating their proteasomal degradation. (b) Inhibitor-treated samples (red) can clearly be separated from 
control samples (black) using principal component analysis. (c) Volcano plot showing significant differences 
(t-test, S0 = 2, permutation-based FDR 5%) in the amount of ubiquitinated peptides. Most viral peptides (black) 
are degraded in a proteasome-dependent manner but not major core proteins A11 and A4 (red). Instead, the 
uncoating factor E5 is proteasomally degraded.
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Methods
Cells and viruses. HeLa cells (ATCC CCL-2) were grown in Eagle’s Minimal Essential Medium (EMEM) 
(Gibco) supplemented with 2 mM L-glutamine (PAA) and 10% (vol/vol) FCS (PAA). HEp-2 (ATCC#CCL-23) 
and Vero E6 cells (ECACC #84113001) were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) 
containing 2 mM L-Glutamine and 5% FCS. The following CPXV strains were used: Brighton Red (BR; NCBI 
GenBank #AF482758.2), RatHei09 (RatHei; NCBI GenBank #KC813504.1), RatKre08 (RatKre; NCBI GenBank 
#KC813505.1), HumGri07 (HumGri; NCBI GenBank #KC813511.1) and HumBer07 (HumBer; NCBI GenBank 
#KC813509.1). Recombinant CPXV expressing red fluorescent protein under an early and green fluorescent pro-
tein under a late viral promotor (CPXV BRFseR) was generously provided by Karsten Tischer (Freie Universität 
Berlin). CPXV proteins are named according to the GRI-90 strain (NCBI GenBank #X94355.2) and protein 
descriptions were obtained from UniProt.
Purification of mature virions. HEp-2 cells were cultured in T175 cm2 cell culture flasks and infected with 
a multiplicity of infection (MOI) of 0.01–0.1. Four days post infection, cells were scraped in culture medium, 
pelleted and resuspended in 10 mM Tris pH 9.0. Cells were disrupted with glass beads and vigorous vortexing 
for 90 s. After sonication for 3 min, glass beads and cell debris were pelleted at 1,000 × g and 4 °C for 5 min. 
Purification of mature virions was done by rate-zonal sucrose gradient centrifugation49 in sterile SW 28 centrifuge 
tubes. For this purpose, the supernatant was centrifuged through a 36% sucrose cushion at 32,900 × g and 4 °C 
for 80 min and the virus pellet was resuspended in 1 ml of 10 mM Tris pH 9.0. The virus suspension was sonicated 
for 1 min, layered on a 24% to 40% continuous sucrose gradient and centrifuged at 26,000 × g and 4 °C for 50 min. 
The virus band was collected and stored at 4 °C, while the pellet was resuspended in 1 ml of 10 mM Tris pH 9.0, 
sonicated and centrifuged through a fresh 24% to 40% continuous sucrose gradient as described. The virus bands 
were pooled and concentrated at 32,900 × g and 4 °C for 60 min. The pellet was resuspended in 1 ml of 10 mM Tris 
pH 9.0 and stored in aliquots at −80 °C.
Plaque assay. The number of PFU was determined by infecting 3 × 105 Vero cells per well in a 24-well plate 
with 200 µl of virus suspension, using serial dilutions ranging from 10−4 to 10−9. Medium containing 1.6% (w/v) 
carboxymethyl cellulose was added 4 h post infection and cells were incubated for 4 days. Fixation of cells was 
done in 3.5% formaldehyde in PBS for 20 min, followed by 20 min of incubation with staining solution (0.1% 
(w/v) naphthol blue black, 1.36% (w/v) sodium acetate and 6% (v/v) acetic acid). PFU per ml were calculated 
using the mean of 4 wells of the same dilution.
Treatment with proteasome inhibitors. MG-132 (Merck) and Bortezomib (New England Biolabs) were 
dissolved in dimethyl sulfoxide (DMSO), diluted with EMEM and sterile filtered through a 0.2 µm filter. If not 
stated otherwise, HeLa cells were treated with proteasome inhibitors simultaneously to infection. Control cells of 
all experiments were treated with the same amount of DMSO as inhibitor-treated cells.
Analysis of proteasome activity. The chymotryptic proteasome activity was analyzed using the 
Proteasome 20 S Activity Assay (Sigma-Aldrich) according to manufacturer’s instructions. Briefly, 10,000 HeLa 
cells per well were seeded into a 96-well opaque black plate and incubated overnight. After three wash steps with 
PBS, cells were treated with 1 and 10 µM MG-132 or 0.01, 0.1 and 1 µM Bortezomib in medium without FCS, and 
the proteasome activity was measured 24 h post inhibitor addition. For this purpose, cells were incubated at 37 °C 
for 4 h with 100 µl/well of Proteasome Assay Loading Solution protected from light, and the fluorescence intensity 
was measured at 525 nm with excitation at 490 nm.
Analysis of proteasome inhibitor-induced cytotoxicity. The release of lactate dehydrogenase (LDH) 
was measured using the LDH Cytotoxicity Assay Kit (Pierce) according to the Chemical Compound-Mediated 
Cytotoxicity Assay Protocol in the manufacturer’s instructions. In summary, 10,000 HeLa cells per well in a clear 
96-well plate were treated with 10 µM MG-132 or 1 µM Bortezomib. After 24 h the LDH release was analyzed 
according to manual instructions.
Analysis of cellular ATP content. The cellular ATP content was analyzed with the CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega). Briefly, 10,000 HeLa cells per well in a 96-well white opaque plate 
were treated with 1 and 10 µM MG-132 or 0.01, 0.1 and 1 µM Bortezomib for 24 h and the ATP content was meas-
ured according to manufacturer’s instructions.
Effect of proteasome inhibition on viral replication. HeLa cells in 24-well plates were infected with CPXV 
BR at an MOI of 1 in the presence or absence of 10 µM MG-132 or 1 µM Bortezomib. After incubation at 4 °C for 1 h the 
virus suspension was removed and cells were washed with PBS and incubated with or without proteasome inhibitors 
for 4 or 24 h. The supernatant was centrifuged at 1,000 × g for 5 min and assayed for genome equivalents (GE) and PFU.
Confocal laser scanning microscopy. A total of 60,000 HeLa cells per well in a 24-well plate were seeded 
on sterile cover slips. Cells were infected with CPXV BRFseR at an MOI of 5 in the presence or absence of 10 µM 
MG-132 or 1 µM Bortezomib. After 8 h cells were washed with PBS and fixed for 1 h in 4% paraformaldehyde in 
PBS. After washing with PBS and water, cells were mounted with Mowiol/DAPI solution (Life Technologies). The 
coverslips were placed on clean microscopy slides and allowed to dry overnight protected from light. Fluorescence 
was observed with a confocal laser scanning microscope (LSM 780, Zeiss).
Electron microscopy. HeLa cells were propagated in T25 cm2 cell culture flasks and pretreated with or 
without 10 µM MG-132 1 h prior to infection with CPXV BRFseR at an MOI of 100. After 4 h of incubation in 
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the presence or absence of MG-132, cells were fixed in 2.5% glutaraldehyde in 0.05 M HEPES pH 7.2 for 2 h at 
room temperature. The samples were post fixed with OsO4 (1% in distilled water, 1 h), tannic acid (0.1% in Hepes 
0.05 M, 30 min) and uranyl acetate (1% in distilled water, 2 h), followed by stepwise dehydration in a graded eth-
anol series and embedding in epon resin which was subsequently polymerized at 60 °C for 48 h50. Thin sections 
were produced with an ultramicrotome (UC7; Leica, Wetzlar, Germany) and counterstained with uranyl acetate 
and lead citrate. The sections were examined using a transmission electron microscope (Tecnai12; FEI) operated 
at 120 kV. For a quantification of intact virus cores and VF, 100 cells were randomly chosen and analyzed at the 
transmission electron microscope.
Determination of viral GE. Viral DNA was isolated from 5 μL of purified virus suspension or from 200 µl of 
HeLa supernatant using the PureLink® Viral RNA/DNA Mini Kit (Life Technologies) according to manufacturer’s 
instructions. DNA was eluted in 50 µl of RNase-free water and viral GE were quantified using an OPV real-time PCR 
assay51. By measuring plasmid standards in the range of 101 to 106 copies per reaction the amount of GE was calculated.
Determination of protein concentration. The protein content was determined via tryptophan fluores-
cence measured with a microplate reader (Tecan Infinite® M1000 PRO)17,52. Briefly, 3 μL of lysate were mixed 
with 197 μL of 8 M urea in 50 mM Tris pH 8.5 (UA) and the fluorescence was measured at 350 nm with 295 nm 
excitation in a white opaque 96-well plate. The tryptophan content was determined by measuring a tryptophan 
standard curve ranging from 0.1 to 0.9 μg of tryptophan. Calculation of protein content was performed by assum-
ing a tryptophan weight content of 1.3% for virus17 and 1.19% for cell lysates52.
Virion lysis and filter-aided sample preparation (FASP). Purified virus particles in 500 µl of 10 mM 
Tris pH 9.0 were pelleted at 25,000 × g and 4 °C for 30 min. Pellets were lysed in 120 μL of 4% SDS, 100 mM Tris 
pH 7.6, 10 mM Tris(2-carboxyethyl)phosphine and 40 mM 2-Chloroacetamide by heating at 95 °C for 5 min. The 
lysates were sonicated for 1 min, clarified at 16,000 × g for 5 min and prepared for MS analysis using a modified 
FASP method53. Briefly, 200 μg of protein were filled up with UA to 230 µl and loaded onto a Microcon Centrifugal 
Filter Unit with 30 kDa MWCO (Merck). Removal of SDS was achieved by washing 3 times with 200 μL of UA. 
Urea was replaced by washing 3 times with 50 mM ammonium bicarbonate (ABC) and digestion was performed 
overnight with Trypsin/Lys-C Mix (Promega) at 37 °C in 40 µl of ABC using an enzyme:protein ratio of 1:25. 
Tryptic peptides were recovered by centrifugation and washing twice with 40 μL of ABC. Peptides were desalted 
with 3 M Mili-SPE Extraction Disc Cartridges C18 SD (Sigma-Aldrich)53 and dried in a vacuum concentrator.
Immunoaffinity purification (IAP) of ubiquitinated peptides. Enrichment of ubiquitinated peptides 
was performed with the PTMScan® Ubiquitin Remnant Motif (K-ε-GG) Kit (New England Biolabs) according to 
the manufacturer’s instructions. Briefly, desalted tryptic peptides were reconstituted in 1.4 ml of IAP buffer and 
incubated with washed motif antibody-bead slurry at 4 °C for 2 h. After 3 washes with IAP buffer and 3 washes 
with MS-grade water, diGly(K) peptides were eluted in 55 µl of 0.15% trifluoroacetic acid, followed by a sec-
ond elution step with 50 µl of 0.15% trifluoroacetic acid. DiGly(K)-enriched peptides were desalted using 200 μl 
StageTips with two Empore™ SPE Disks C18 (3 M Purification)54 and concentrated in a vacuum concentrator.
Effect of proteasome inhibition on ubiquitinated peptides in CPXV-infected HeLa cells. HeLa 
cells in T75 cm2 cell culture flasks were pretreated with or without 10 µM MG-132 at 37 °C for 1 h and infected 
with CPXV BR at an MOI of 50 in the presence or absence of proteasome inhibitor (triplicates). After 2 h post 
infection cells were scraped into medium and washed twice with PBS. Cell pellets were lysed and digested with 
FASP prior to enrichment of diGly(K) peptides analogous to virions.
LC-MS/MS analysis. Analysis of diGly(K)-enriched peptides was performed with an Easy-nanoLC (Thermo 
Fisher Scientific) coupled to an LTQ Orbitrap Discovery mass spectrometer (Thermo Fisher Scientific). For 
single-run shotgun analysis, peptides were reconstituted in 0.1% formic acid and quantified by absorbance meas-
urement at 280 nm using a Nanodrop (Thermo Fisher Scientific). Identical peptide amounts were loaded on a 
Reprosil-Pur 120 C18-AQ, 2.4 μm, 300 mm × 75 μm fused silica capillary column (Dr. Maisch) and separated 
with a linear 90 min gradient of acetonitrile in 0.1% formic acid and 3% DMSO from 0 to 40% at a flow rate of 
200 nl/min. The column heater temperature was set to 60 °C and a spray voltage of 2.0 kV was applied. For back-
ground ion reduction an ABIRD device was used. The transfer capillary was heated to 275 °C without applying 
sheath or auxiliary gas flow. The orbitrap mass analyzer operated at a resolution of 30,000, scanning a mass range 
of 300–1,250 m/z. Data-dependent fragmentation of the 12 most intense ions with charge state ≥ 1 + was per-
formed using CID fragmentation in the ion trap applying 35% normalized collision energy. The threshold for MS² 
spectra selection was set to 500 counts with maximally allowed ion accumulation times of 500 ms for full scan and 
150 ms for fragment spectra. Viral peptides were analyzed in technical duplicates.
MS data analysis. DiGly(K) peptides were identified with SEQUEST database search algorithm imple-
mented in the Proteome Discoverer computational proteomics platform (v2.1). MS2 spectra of both technical 
duplicates were searched against the human UniProt complete proteome set with isoforms, the protein sequences 
of the respective CPXV strain and a contaminant database (cRAP). All CPXV databases were translated from the 
genome sequence (NCBI GenBank: BR #AF482758.2; Hei #KC813504.1; Kre #KC813505.1; Ber #KC813509.1 
and Gri #KC813511.1). The enzyme specificity was set to trypsin (full) allowing for two missed cleavages. Mass 
tolerances were 10 ppm for parent ions and 0.6 Da for fragment ions. The maximum number of dynamic mod-
ifications per peptide was set to 4, including methionine oxidation, protein N-terminus acetylation and diGly 
modification of lysine residues. Cysteine carbamidomethylation was set as static modification. Peptides were 
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identified with a false discovery rate (FDR) of 1% estimated by Percolator algorithm55, and peptide areas were 
calculated using the Precursor Ions Area Detector node.
Identification and label-free quantification of ubiquitinated peptides in HeLa cells was performed using the 
Andromeda56 and the MaxLFQ algorithm57, respectively, implemented in the MaxQuant computational proteom-
ics platform (v1.5.1.2)58. MS2 spectra were searched against the human UniProt complete proteome set including 
isoforms, the CPXV BR database and a contaminant database applying specific trypsin/P digestion with a maxi-
mum of two missed cleavages. Variable and fixed modifications were set analogous to those of the virion peptide 
identification. Mass tolerances were 4.5 ppm for parent ions and 0.5 Da for fragment ions. A strict peptide FDR 
of 1% was applied while protein FDR was neglected. The match-between-runs option was used to transfer pep-
tide identifications between samples within a match time window of 0.7 min and an alignment time window of 
20 min. Further bioinformatics analysis of peptide identifications was done in Perseus (v1.5.0.31)59. Therefore, 
peptide raw intensities were filtered for reverse and contaminant peptide hits. Log2 transformed peptide intensi-
ties were normalized by median column subtraction and peptides with at least one diGly(K) modification were 
kept for further analysis. Categorically annotated control and inhibitor-treated replicates were filtered for at least 
three valid values in at least one group and normalized by median row subtraction. Missing values were imputed 
from normal distribution with default values mimicking low abundance measurements (width 0.3, down shift 
1.8). Significant differences of ubiquitinated peptide quantities were analyzed using a two-sided t-test (S0 = 2) 
with 5% permutation-based FDR and 250 randomizations.
Data availability. The MS proteomics data have been deposited to the ProteomeXchange Consortium via 
the PRIDE60 partner repository with the dataset identifier PXD006426.
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